Stock results analysis for Industry - Biotechnology for Q2 FY25-26 ending Sep 30, 2025

Analysis of which stocks have performed the best and worst in Industry - Biotechnology for Q2 FY25-26 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current quarter are considered.

Stock universe
2
POSITIVE PROFIT GROWTH
7
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
16.0 %
TOTAL REVENUE GROWTH
10.7 %
TOTAL EBIDT GROWTH
10.0 %
TOTAL OPER. PROFIT GROWTH
 Positive  Negative  Pending
Stock Last Result Updated Market Capitalization Current Price Operating Revenue Qtr Revenue Growth Qtr YoY % Revenue Surprise Qtr % Net Profit Qtr Net Profit Qtr Growth YoY % Net Profit Surprise Qtr % Operating Profit Qtr Operating Profit Growth Qtr YoY % EBITDA Qtr EBITDA Qtr growth YoY % Operating Profit Margin Qtr % Operating Profit Qtr Margin% YoY Change
Alpa Laboratories 15-Nov-2025 166.66 79.21 - -
Biocon 11-Nov-2025 52195.06 390.40 2.31 9.37
Panacea Biotec 14-Nov-2025 2367.65 386.55 - -
Vivo Bio Tech 14-Nov-2025 50.61 31.38 - -
Genesis IBRC 14-Nov-2025 111.41 85.70 - -
Genomic Valley Biotech 15-Oct-2025 7.55 24.73 - -
Shree Ganesh Bio-Tech 08-Nov-2025 24.32 0.61 - -
Advanced Enzyme 12-Nov-2025 3356.68 299.90 2.57 -
Concord Biotech 13-Nov-2025 14026.94 1340.80 -15.77 -8.78